Clinical Data ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D Pharmaceutical TechnologyData presented at ACC 2026 suggests that dulaglutide may be stabilising coronary plaques from the inside out, as well as managing diabetes.Clinical DataCardiovascularRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Technology Data presented at ACC 2026 suggests that dulaglutide may be stabilising coronary plaques from the inside out, as well as managing diabetes. Clinical DataCardiovascularRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave CrashesNext: Viridian reports positive results from elegrobart phase 3 trial Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
